Tri-sialic acid for treatment of EKC
| Reference number | |
| Coordinator | Adenovir Pharma AB |
| Funding from Vinnova | SEK 527 413 |
| Project duration | May 2014 - February 2015 |
| Status | Completed |
Purpose and goal
The lead molecule, APD-514, has been synthesized in sufficient quantities for early pre-formulation in an eye drop formulation and been tested in in vitro efficacy studies and in pre-clinical toxicity studies. APD-514 show good solubility and compability with commonly used excipients, excellent in vitro efficacy. Stablity is good, no degradation found. APD-514 show lack of toxicity in rat and rabbit and is safe and well tolerated. The PCT is judged to be patentable. A Business Plan has been written with a clear project plan going forward APD-514 is a promising new drug candidate.
Results and expected effects
APD-514 synthesis in lab-scale exceeded expected yeald. Good solubility and compability with commonly used excipients. Stablity is good, no degradation. Further development is needed for optimal formulation. Excellent in vitro efficacy. APD-514 show lack of toxicity in rat and rabbit and is safe and well tolerated. The PCT is judged to be patentable. A Business Plan summarize plan going forward with a clear project plan. APD-514 is a promising new drug candidate.
Approach and implementation
The project has been executed according to plan, all goals have been met. Collaboration with Dept of Chemistry and Microbiology at Umeå University and Medigelium has worked well. Collaboration with Swetox for QSAR and Adlego for pre-clinical tox-studies has worked well, as well as with patent firm Ström & Gulliksson. Business Plan with forward looking projekt plan has been written together with the innovators.